Condition: Mantle Cell Lymphoma · Sponsor: City of Hope Medical Center
The purpose of this study is to determine if giving an experimental drug called venetoclax in combination with lenalidomide and rituximab is safe and effective for treating people with Mantle Cell Lymphoma (MCL).
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| City of Hope Medical center | Duarte, California, United States | Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| The Ohio State University Comprehensive Cancer Center | Columbus, Ohio, United States | Not Yet Recruiting |
| University of Virginia Cancer Center | Charlottesville, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03523975